Enliven Therapeutics, Inc. (IMRA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Enliven Therapeutics, Inc. (IMRA)
Company Performance

Current Price

as of Oct 16, 2024

$28.12

P/E Ratio

N/A

Market Cap

$1.33B

Description

Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.

Metrics

Overview

  • HQBoulder, CO
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerIMRA
  • Price$28.12+1.08%

Trading Information

  • Market Cap$1.33B
  • Float61.39%
  • Average Daily Volume (1m)358,604
  • Average Daily Volume (3m)234,942
  • EPS-$1.93

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$19.95M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$24.52M
  • EV$811.24M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B4.35
Documents